Interim Results for the Six Months Ended 30 June 2024
23. September 2024 08:42 ET
|
OXB
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration...
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO
18. September 2024 07:00 ET
|
OXB
Oxford Biomedica rebrands as OXB reinforcing transformation into leading global cell and gene therapy CDMO Oxford, UK – 18 September 2024: OXB (LSE:OXB), a quality and innovation-led cell and gene...
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today
02. September 2024 07:00 ET
|
Oxford BioMedica plc
Lucinda Crabtree joins Oxford Biomedica as Chief Financial Officer today Oxford, UK – 2 September 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”, "OXB" or “the Company”), a quality and...
Oxford Biomedica to host a free webinar showcasing its AAV expertise
27. August 2024 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica to host a free webinar showcasing its AAV expertise Oxford, UK - 27 August 2024: On Wednesday 11 September 2024, Oxford Biomedica, a quality and innovation-led cell and gene therapy...
Oxford Biomedica – Half Year Trading Update and Notice of Interim Results
08. August 2024 07:00 ET
|
Oxford BioMedica plc
Half Year Trading Update and Notice of Interim Results Full year 2024 revenue and medium-term financial guidance reiterated; underpinned by OXB’s growing market share in the expanding cell and gene...
Oxford Biomedica announces CFO transition
17. Juli 2024 07:06 ET
|
Oxford BioMedica plc
Oxford Biomedica announces Chief Financial Officer transition - Lucinda Crabtree to join as Chief Financial Officer - Oxford, UK – 17 July 2024: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica”,...
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results
05. März 2024 07:00 ET
|
Oxford BioMedica plc
Update to Medium-Term Financial Guidance and 2023 Trading and Notice of Preliminary Results Three-year revenue CAGR increased to more than 35%, up from prior guidance of more than 30%Projected FY2024...
Oxford Biomedica completes acquisition of ABL Europe
29. Januar 2024 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica completes acquisition of ABL Europe Strengthens Oxford Biomedica’s position as a global pure-play cell and gene therapy CDMO with multi viral vector capabilities across multiple...
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing
23. Januar 2024 07:00 ET
|
Oxford BioMedica plc
Oxford Biomedica is hosting a free webinar to share clients’ success stories in viral vector manufacturing Oxford, UK – 23 January 2024: On Wednesday 7 February, Oxford Biomedica, a quality and...
Business Update
07. Dezember 2023 07:00 ET
|
Oxford BioMedica plc
Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)On...